Brian Till, MDDr. Till specializes in autologous stem cell transplantation to treat lymphoma and multiple myeloma, as well as adoptive T cell therapy clinical trials for lymphoma.
Patient Care Philosophy:
It is important to me to listen to patients and communicate openly with them, to make sure they understand their disease and the treatment options. I place great value in developing a trusting relationship with each patient. My goal is to design a personalized treatment plan based on the best current medical evidence. I believe it is important to offer patients treatment on clinical trials whenever possible, since this is the only way to develop better therapies for cancer.
Dr. Till's Resume
Research Associate, Fred Hutchinson Cancer Research Center
Acting Instructor, University of Washington School of Medicine
- Hematology Oncology
Dr. Till specializes in autologous stem cell transplantation to treat lymphoma and multiple myeloma, as well as adoptive T cell therapy clinical trials for lymphoma.
Education And Training
- MD, University of Chicago School of Medicine, Chicago, IL
- Residency Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- Fellowship Oncology, Fred Hutchinson Cancer Research Center/ University of Washington, Seattle, WA
More InformationFor more information about Dr. Brian Till's clinical and research expertise, click here.
Visit PubMed for a full listing of Dr. Till's journal articles.
Dr. Till's Story
Dr. Brian Till was impressed with the doctors who had treated him for various things growing up, "and I wanted to be able to help others in the same way," he says. "I had always had an interest in science as well as some early research experiences in college that I really enjoyed, so a career in medicine made sense."
During his internal medicine residency, Till found that the relationships he had with cancer patients were more meaningful than with any other specialty. Together with his interest in cancer research, medical oncology was an easy choice.
In regards to cancer treatment in the future, "I hope that as immunologically based treatments improve, we will be able to kill patients’ cancer cells with few side effects, and will be able to eradicate those persistent cancer cells that currently are not killed by chemotherapy, leading to more cures," he says. "Moreover, as sequencing capabilities improve and we become able to determine the exact mutations present in each patient’s cancer, I hope that we will be able to craft specific therapies tailored to each patient’s disease."
Dr. Till's research involves trying to train patients’ own immune cells (T cells) to fight their cancer, a field called adoptive T cell therapy. "We take some T cells from the blood of patients with lymphoma, use gene therapy to help the cells recognize a marker on the lymphoma cells, and then grow the cells in the laboratory. When there are enough cells, we re-infuse them back into the patient with the goal of attacking their lymphoma."
When he isn't caring for patients or conducting research, Dr. Till likes to unwind by spending time with his family, hiking, reading, and traveling.